295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial

@inproceedings{Grothey2003295CP,
  title={295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial},
  author={Axel F Grothey and Karin Jordan and Olaf Kellner and C. Constantin and Georg Dietrich and Hendrik Kroening and Luisa Mantovani and Christoph Schlichting and Helmut Forstbauer and Hans Joachim Schmoll},
  year={2003}
}

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

Treatment of metastatic colorectal cancer.

  • Seminars in oncology
  • 2011
VIEW 2 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
VIEW 1 EXCERPT
CITES BACKGROUND